PMID- 22340363
OWN - NLM
STAT- MEDLINE
DCOM- 20121105
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 14
IP  - 8
DP  - 2012 Aug
TI  - The effect of linagliptin on glycaemic control and tolerability in patients with 
      type 2 diabetes mellitus: a systematic review and meta-analysis.
PG  - 694-708
LID - 10.1111/j.1463-1326.2012.01586.x [doi]
AB  - AIM: Linagliptin is a new dipeptidyl peptidase-4 inhibitor recently approved for 
      use in the USA. The objective of this systematic review and meta-analysis was to 
      assess effect of linagliptin on glycaemic control, biomarkers and incidence of 
      adverse events (AEs) in patients with type 2 diabetes mellitus. METHODS: Five 
      published and four unpublished randomized, clinical trials were identified from 
      multiple databases. Qualitative assessments and quantitative analyses were 
      performed. RESULTS: Nine studies included 4246 participants with 53% men, 59.4% 
      Caucasians, 38.7% Asians, and age range 45-69 years. Linagliptin was given as 
      monotherapy (vs. placebo) or combined with metformin (vs. metformin + placebo), 
      sulphonylurea (vs. sulphonylurea + placebo) or pioglitazone (vs. pioglitazone + 
      placebo). Linagliptin 5 mg/day for 12-24 weeks, significantly reduced haemoglobin 
      A1c (HbA1c) (-0.63%, p < 0.00001), fasting plasma glucose (FPG) (-1.01 mmol/l, p 
      < 0.00001) and improved disposition index (DI, product of insulin sensitivity and 
      acute insulin secretion) (p = 0.0001). Linagliptin monotherapy was not more 
      effective than metformin at reducing HbA1c or FPG. Similar proportion of patients 
      in linagliptin and placebo groups reported AEs including upper respiratory tract 
      infections, headaches, nausea, hypertension and back pain. CONCLUSIONS: 
      Linagliptin was associated with modest but significant reduction in HbA1c and FPG 
      and improved DI after 12-24 weeks. Patients who would probably benefit most are 
      those with HbA1c <9%, already on an active agent, compliant with weight reduction 
      strategies, and can recognize and manage hypoglycaemia, fluid retention and upper 
      respiratory tract infections. Long-term studies are needed to determine 
      durability of response, incidence of microvascular and macrovacular 
      complications, cost-effectiveness and safety.
CI  - (c) 2012 Blackwell Publishing Ltd.
FAU - Singh-Franco, D
AU  - Singh-Franco D
AD  - Pharmacy Practice, Nova Southeastern University, College of Pharmacy, FL 33324, 
      USA. singh@nova.edu
FAU - McLaughlin-Middlekauff, J
AU  - McLaughlin-Middlekauff J
FAU - Elrod, S
AU  - Elrod S
FAU - Harrington, C
AU  - Harrington C
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20120320
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Purines)
RN  - 0 (Quinazolines)
RN  - 0 (Thiazolidinediones)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 9100L32L2N (Metformin)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
CIN - Diabetes Obes Metab. 2012 Nov;14(11):1054-5. PMID: 23034010
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/*metabolism
MH  - Cost-Benefit Analysis
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*administration & dosage
MH  - Linagliptin
MH  - Male
MH  - Metformin/*administration & dosage
MH  - Middle Aged
MH  - Pioglitazone
MH  - Purines/*administration & dosage
MH  - Quinazolines/*administration & dosage
MH  - Randomized Controlled Trials as Topic
MH  - Thiazolidinediones/*administration & dosage
MH  - Treatment Outcome
MH  - United States
EDAT- 2012/02/22 06:00
MHDA- 2012/11/06 06:00
CRDT- 2012/02/21 06:00
PHST- 2012/02/21 06:00 [entrez]
PHST- 2012/02/22 06:00 [pubmed]
PHST- 2012/11/06 06:00 [medline]
AID - 10.1111/j.1463-1326.2012.01586.x [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2012 Aug;14(8):694-708. doi: 
      10.1111/j.1463-1326.2012.01586.x. Epub 2012 Mar 20.